StockNews.com Downgrades Gilead Sciences (NASDAQ:GILD) to Buy

Gilead Sciences (NASDAQ:GILD – Get a Free Report) was downgraded from a “strong buy” rating to a “buy” rating by StockNews.com in a research note issued to investors on Friday.

Other equity analysts have also recently issued research reports on the stock. Oppenheimer reissued an “outperform” rating and set a $105.00 price target on shares of Gilead Sciences in a report on Friday. Barclays lowered their price target on shares of Gilead Sciences from $85.00 to $80.00 and set an “equalweight” rating for the company in a report on Monday, February 12. UBS Group lowered its price target on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a report on Wednesday. Truist Financial downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating and lowered their price target for the company from $91.00 to $82.00 in a report on Thursday, February 22. Finally, Mizuho lowered their price target on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the company in a report on Thursday, February 22. One research analyst has rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $84.71.

Check out our latest research report on Gilead Sciences

Gilead Sciences stock performance

Shares of Gilead Sciences opened at $66.76 on Friday. The company has a market cap of $83.12 billion, a price-to-earnings ratio of 14.84, a price-to-earnings ratio of 0.91 and a beta of 0.19. The company has a fifty day moving average of $71.96 and a two hundred day moving average of $76.56. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27. Gilead Sciences has a 12-month low of $65.90 and a 12-month high of $87.86.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last released its quarterly earnings data on Tuesday, February 6. The biopharmaceutical company reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). The company had revenue of $7.12 billion during the quarter, compared to analyst estimates of $7.10 billion. Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The company’s revenue for the quarter fell 3.7% compared to the same quarter last year. During the same period last year, the company earned $1.67 in earnings per share. Research analysts expect Gilead Sciences to post 6.55 earnings per share for the current year.

Insiders place their bets

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Monday, April 1st. The shares sold at an average price of $72.96, for a total value of $145,920.00. Following the sale, the insider now directly owns 96,304 shares in the company, valued at $7,026,339.84. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.16% of the shares are owned by company insiders.

Institutional investors are weighing in on Gilead Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Altshuler Shaham Ltd increased its position in Gilead Sciences by 7.0% in the fourth quarter. Altshuler Shaham Ltd now owns 1,856 shares of the biopharmaceutical company’s stock worth $159,000 after acquiring an additional 121 shares in the last quarter. Nilsine Partners LLC increased its stake in Gilead Sciences by 1.1% during the third quarter. Nilsine Partners LLC now owns 11,894 shares of the biopharmaceutical company’s stock worth $891,000 after purchasing an additional 127 shares during the period. Etesian Wealth Advisors Inc. increased its stake in Gilead Sciences by 0.7% during the 4th quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock worth $1,486,000 after purchasing an additional 128 shares during the period. Financial Counselors Inc. increased its stake in Gilead Sciences by 1.5% during the 4th quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock worth $718,000 after purchasing an additional 128 shares during the period. Finally, Revolve Wealth Partners LLC increased its holdings in Gilead Sciences by 3.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock worth $292,000 after purchasing an additional 130 shares during the period. 83.67% of the shares are currently held by institutional investors.

Gilead Sciences Company Profile

(Get a free report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops and commercializes medicines addressing unmet medical needs in the United States, Europe and internationally. The company provides products from Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, Sunlencs and Atripla for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy and Viread for the treatment of viral hepatitis.

Read further

Get daily news and reviews for Gilead Sciences – Enter your email address below to receive a concise daily digest of the latest news and analyst ratings for Gilead Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.